Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Chronometriq

Explore full profile

A healthcare productivity suite made for you To reduce absenteeism, reduce your operating costs or find new patients, we can help!

Montreal, CanadaFounded 2012Health Tech & Medtech
Valuation $50–100M Last recorded · 2019
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Chronometriq and the history behind them.

About Chronometriq

Chronometriq is a company specializing in digital appointment management products designed to improve the efficiency of healthcare providers and enhance the patient experience. Operating primarily in the North American market, Chronometriq serves a diverse range of clients including healthcare professionals, clinics, and medical centers. The company's core offerings include online appointment booking, automated appointment reminders, and self-check-in kiosks, all of which integrate seamlessly with existing Electronic Medical Records (EMR) systems. By reducing the administrative burden on healthcare staff, Chronometriq helps clinics lower operating costs and minimize appointment absenteeism. The business model is subscription-based, generating revenue through recurring fees for its software solutions. Chronometriq's user-friendly and flexible platform has earned the trust of a rapidly growing community of healthcare professionals and patients.

Source: Dealroom company data

At a glance

Status
Closed
Founded
2012
Headquarters
Montreal, Canada
Employees
39
Open positions
None listed
Dealroom signal
0.0/100
Industry
Health
Sub-industry
Medical Devices, Health Platform
Sector
Health Tech & Medtech, Hospital, Health Office Tools, Hard Tech, Health It
Client focus
b2b
Investment activity
1 company, latest Jul 2020
Capital deployed
—
Preferred round
ACQUISITION

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCEquity / VC Jul 2021 $3.2M $13M Undisclosed —
DEBT✓Debt Oct 2020 $5M — Canadian Imperial Bank of Commerce —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Chronometriq website traffic

Latest recorded traffic for Chronometriq is 130 monthly website visits. Chronometriq's team declined 9.3% over the past year.

Latest monthly visits130 1-year team growth-9.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Bridgescale Partners
  • Full in partners

Series B and later1 investor entered at this stage

  • Canadian Imperial Bank of Commerce
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇦 Canada · Montreal HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Chronometriq on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Chronometriq’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.